Please ensure Javascript is enabled for purposes of website accessibility

Why Biogen Stock Is On Fire Today

By George Budwell - Jun 7, 2021 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's controversial Alzheimer's disease drug got a green light from the FDA.

What happened

Biotech heavyweight Biogen (BIIB -1.04%) is poised for a sizable jump in its share price later today once the trading halt on its stock is lifted following the surprise Food and Drug Administration approval of its controversial Alzheimer's disease drug aducanumab. The biotech's partner on this project, Eisai (ESALY -3.63%), is enjoying a banner day in the market in the wake of this news, with the Japanese biopharma's shares rising by an astounding 45% as of 11:24 a.m. EDT Monday morning. 

So what

Aducanumab is the first drug ever approved to treat the underlying cause of this deadly mind-wasting disease, although the drug failed one of its two pivotal trials, leading to controversy surrounding the FDA's approval.

But with over 5.8 million American adults currently afflicted with this neurodegenerative disease, according to estimates from the Centers for Disease Control and Prevention, Wall Street expects the drug to generate over $5.7 billion in revenue by 2027.

A daughter comforting her mother.

Image source: Getty Images.

That's great news for Biogen and its shareholders. The biotech, after all, has been staring down significant competitive threats to both its multiple sclerosis and spinal muscular atrophy franchises over the last year. 

Now what

Is Biogen's stock a screaming buy after this landmark regulatory approval? That's a strong yes. While there are several other experimental Alzheimer's drugs in the pipeline across the industry, Biogen should have the market to itself for the foreseeable future. What this means is that Wall Street's initial sales estimates, while stately in their own right, might be woefully low.

The fact is that Biogen might ultimately generate upward of $10 billion per year from aducanumab, making it one of the best-selling drugs of all time. With that kind of revenue stream, this titan of the biotech world should have little trouble rounding out its pipeline through various business development activities, as well as rewarding shareholders with share buybacks and perhaps even a dividend in the second half of the decade. 


George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
$214.09 (-1.04%) $-2.25
Eisai Co., Ltd. Stock Quote
Eisai Co., Ltd.
$43.26 (-3.63%) $-1.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.